Table 1.

Patient data and outcome

Number	Age	Indication	Location	Type	Rot/deg.	Compl.	Rev.	FU (month)
1	81	BCC UL	J	P	120	N	N	63
2	74	LM C	Z	P	90	N	N	60
3	60	BCC Ns	NL	P	150	Ya	N	59
4	73	BCC Ns	NL	P	150	N	N	58
5	–	DS Ns	NL	VY		N	N	58
6	86	MB Ns	ST	P	180	Yb	N	57
7	80	BCC UL	NL/J	VY		N	N	56
8	71	BCC AN	NL	P	180	N	N	52
9	83	BCC UL	NL/J	VY		N	N	40
10	79	BCC Ns	NL	P	180	N	Mi	37
11	38	BCC AN/UL	NL	P	180	N	Mi	24
12	–	BCC UL+	NL	VY		N	N	24
13	74	AK Ns	ST	P	180	N	N	15
14	78	BCC AN	NL	P	180	N	Mi	15
15	68	BCC FH	ST	P	150	N	Mi	14
16	70	BCC Ns	NL	P	180	N	N	13
17	83	SCC C	NL/C	VY		N	N	8
18	59	BCC AN	NL	P	180	N	N	6
19	73	BCC Ns	NL	P	180	N	N	4
20	54	MM UL	J	P	135	N	N	3
21	79	BCC Mc	OO	P	150	N	N	1

Compl. complications, Rev. revision, FU follow-up, Rot/deg degree of rotation, BCC basal cell carcinoma, AN ala nasi, NL nasolabial, P propella, Mi minor revision/contouring, UL upper lip, VY VY advancement flap, J jowel, UL + upper lip and adjacent aesthetical unit, MC medial canthus, DS donor site, Ns nose, MB Morbus Bowen, FH forehead, ST supratrochlear, LM lentigo maligna, Z zygomatic, AK actinic keratosis, C cheek, OO orbicularis oculi, SCC squamous cell carcinoma, MM malignant melanoma, N noY yes

^aPartial flap loss

^bVenous congestion